INS and metabolic disease: Importantly, plasma FAM3A levels were decreased along with metabolic disorders (Fig. 3g), consistent with previous studies reporting that FAM3A expression was downregulated in liver cells treated with high-lipid [40] and that chronic exposure to high concentrations of insulin repressed FAM3A expression in HepG2 cells [8].